153 related articles for article (PubMed ID: 25943718)
1. Thrombotic microangiopathy, cancer, and cancer drugs.
Izzedine H; Perazella MA
Am J Kidney Dis; 2015 Nov; 66(5):857-68. PubMed ID: 25943718
[TBL] [Abstract][Full Text] [Related]
2. Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma.
Hamad CD; Hoelscher ZC; Tchakarov A; Kala J
CEN Case Rep; 2022 Aug; 11(3):321-327. PubMed ID: 34997535
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic microangiopathy with targeted cancer agents.
Blake-Haskins JA; Lechleider RJ; Kreitman RJ
Clin Cancer Res; 2011 Sep; 17(18):5858-66. PubMed ID: 21813634
[TBL] [Abstract][Full Text] [Related]
4. Pegylated Liposomal Doxorubicin Causes Kidney-limited Thrombotic Microangiopathy.
Glezerman I; Salvatore S; Tap W; Kelly C; Brauer Ornelas CM; Shaikh A
Am J Kidney Dis; 2024 Apr; 83(4):549-553. PubMed ID: 37839689
[TBL] [Abstract][Full Text] [Related]
5. Fruquintinib-induced renal-limited thrombotic microangiopathy: a case report.
Zhao R; Fan R; Pan Y; Han Y; Wang Y; Chen W
BMC Nephrol; 2024 May; 25(1):170. PubMed ID: 38762494
[TBL] [Abstract][Full Text] [Related]
6. Surufatinib-induced renal thrombotic microangiopathy: first case report and review of literature.
Zhu W; Wang W; Shi Y; Shen B; Li Y
Virchows Arch; 2023 Oct; 483(4):561-567. PubMed ID: 37101053
[TBL] [Abstract][Full Text] [Related]
7. Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database.
Klomjit N; Evans R; Le TK; Wells SL; Ortega J; Green-Lingren O; Mazepa M; Sise ME; Jhaveri KD; Gupta S
Am J Hematol; 2023 Dec; 98(12):E369-E372. PubMed ID: 37740927
[TBL] [Abstract][Full Text] [Related]
8. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.
Kavanagh D; McGlasson S; Jury A; Williams J; Scolding N; Bellamy C; Gunther C; Ritchie D; Gale DP; Kanwar YS; Challis R; Buist H; Overell J; Weller B; Flossmann O; Blunden M; Meyer EP; Krucker T; Evans SJ; Campbell IL; Jackson AP; Chandran S; Hunt DP
Blood; 2016 Dec; 128(24):2824-2833. PubMed ID: 27663672
[TBL] [Abstract][Full Text] [Related]
9. A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER.
Hunt R; Yalamanoglu A; Tumlin J; Schiller T; Baek JH; Wu A; Fogo AB; Yang H; Wong E; Miller P; Buehler PW; Kimchi-Sarfaty C
Blood; 2017 Feb; 129(7):896-905. PubMed ID: 27864296
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic microangiopathy after kidney transplantation: Expanding etiologic and pathogenetic spectra.
Mubarak M; Raza A; Rashid R; Sapna F; Shakeel S
World J Transplant; 2024 Mar; 14(1):90277. PubMed ID: 38576763
[TBL] [Abstract][Full Text] [Related]
11. Management of Snakebite-Induced Thrombotic Microangiopathy (TMA) With Plasmapheresis.
Shankar T; Kaeley N; Rajta M; Pundir A; Kaushik A
Cureus; 2023 Dec; 15(12):e50104. PubMed ID: 38186452
[TBL] [Abstract][Full Text] [Related]
12. Plasma exchange for treatment of a therapy-related thrombotic microangiopathy in a patient with advanced hepatocellular carcinoma-A case report.
Stortz M; Shmanko K; Kraus D; Gairing S; Boedecker-Lips S; Förster F; Weinmann A; Weinmann-Menke J
Clin Case Rep; 2023 Nov; 11(11):e8124. PubMed ID: 37953891
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine-Related Thrombotic Microangiopathy.
Mateo FJP; Guasch AD; Pineda JAG; Manrique ACV; Cullell BM; López-Bravo DP; Díaz JG; Cascón AP; Freiria XB
J Gastrointest Cancer; 2024 Jan; ():. PubMed ID: 38175385
[TBL] [Abstract][Full Text] [Related]
14. [Renal Side Effects of Novel Molecular Targeted Oncologic Agents].
Fenoglio R; Cortazzi S; Marchisio M; Rabajoli G; Terzolo E; Sciascia S; Roccatello D
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007829
[TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF Cancer Therapy in Nephrology Practice.
Izzedine H
Int J Nephrol; 2014; 2014():143426. PubMed ID: 25210627
[TBL] [Abstract][Full Text] [Related]
16. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS).
Wong E; Challis R; Sheerin N; Johnson S; Kavanagh D; Goodship TH
Immunobiology; 2016 Jun; 221(6):715-8. PubMed ID: 26037115
[TBL] [Abstract][Full Text] [Related]
17. Managing atypical hemolytic uremic syndrome: chapter 2.
Nester CM
Kidney Int; 2015 May; 87(5):882-4. PubMed ID: 25951068
[TBL] [Abstract][Full Text] [Related]
18. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting.
Salvadori M; Rosso G; Bertoni E
World J Nephrol; 2015 May; 4(2):169-84. PubMed ID: 25949931
[TBL] [Abstract][Full Text] [Related]
19. Managing thrombocytopenia associated with cancer chemotherapy.
Kuter DJ
Oncology (Williston Park); 2015 Apr; 29(4):282-94. PubMed ID: 25952492
[TBL] [Abstract][Full Text] [Related]
20. Re-examination of 30-day survival and relapse rates in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
Bittencourt CE; Ha JP; Maitta RW
PLoS One; 2015; 10(5):e0127744. PubMed ID: 26000799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
